{"protocolSection": {"identificationModule": {"nctId": "NCT00927901", "orgStudyIdInfo": {"id": "CQAB149D2301"}, "secondaryIdInfos": [{"id": "2009-010589-46", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma", "officialTitle": "A Multi-centre, Randomized, Double-blind, Placebo-controlled, Multiple-dose, 4-way Crossover Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Indacaterol Salts (Maleate, Xinafoate, and Acetate) in Patients With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2013-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-06"}, "primaryCompletionDateStruct": {"date": "2009-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-06-24", "studyFirstSubmitQcDate": "2009-06-24", "studyFirstPostDateStruct": {"date": "2009-06-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-07-29", "resultsFirstSubmitQcDate": "2011-07-29", "resultsFirstPostDateStruct": {"date": "2011-08-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-08-26", "lastUpdatePostDateStruct": {"date": "2013-09-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study assessed the efficacy, safety, and pharmacokinetics of indacaterol salts (maleate, xinafoate and acetate) in patients with asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["QAB149", "asthma", "indacaterol salts (acetate, maleate, and xinafoate)", "orally inhaled indacaterol salts", "persistent asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate", "type": "EXPERIMENTAL", "description": "In treatment period 1, patients received indacaterol maleate 400 \u03bcg; in treatment period 2, patients received placebo to indacaterol; in treatment period 3, patients received indacaterol xinafoate 400 \u03bcg; and in treatment period 4, patients received indacaterol acetate 400 \u03bcg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol maleate 400 \u03bcg", "Drug: Indacaterol acetate 400 \u03bcg", "Drug: Indacaterol xinafoate 400 \u03bcg", "Drug: Placebo to indacaterol"]}, {"label": "Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo", "type": "EXPERIMENTAL", "description": "In treatment period 1, patients received indacaterol xinafoate 400 \u03bcg; in treatment period 2, patients received indacaterol maleate 400 \u03bcg; in treatment period 3, patients received indacaterol acetate 400 \u03bcg; and in treatment period 4, patients received placebo to indacaterol 400 \u03bcg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol maleate 400 \u03bcg", "Drug: Indacaterol acetate 400 \u03bcg", "Drug: Indacaterol xinafoate 400 \u03bcg", "Drug: Placebo to indacaterol"]}, {"label": "Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate", "type": "EXPERIMENTAL", "description": "In treatment period 1, patients received indacaterol acetate 400 \u03bcg; in treatment period 2, patients received indacaterol xinafoate 400 \u03bcg; in treatment period 3, patients received placebo to indacaterol; and in treatment period 4, patients received indacaterol maleate 400 \u03bcg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol maleate 400 \u03bcg", "Drug: Indacaterol acetate 400 \u03bcg", "Drug: Indacaterol xinafoate 400 \u03bcg", "Drug: Placebo to indacaterol"]}, {"label": "Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate", "type": "EXPERIMENTAL", "description": "In treatment period 1, patients received placebo to indacaterol; in treatment period 2, patients received indacaterol acetate 400 \u03bcg; in treatment period 3, patients received indacaterol maleate 400 \u03bcg; and in treatment period 4, patients received indacaterol xinafoate 400 \u03bcg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol maleate 400 \u03bcg", "Drug: Indacaterol acetate 400 \u03bcg", "Drug: Indacaterol xinafoate 400 \u03bcg", "Drug: Placebo to indacaterol"]}], "interventions": [{"type": "DRUG", "name": "Indacaterol maleate 400 \u03bcg", "description": "Indacaterol maleate 400 \u03bcg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol.", "armGroupLabels": ["Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate", "Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate", "Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo", "Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate"]}, {"type": "DRUG", "name": "Indacaterol acetate 400 \u03bcg", "description": "Indacaterol acetate 400 \u03bcg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol.", "armGroupLabels": ["Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate", "Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate", "Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo", "Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate"]}, {"type": "DRUG", "name": "Indacaterol xinafoate 400 \u03bcg", "description": "Indacaterol xinafoate 400 \u03bcg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol.", "armGroupLabels": ["Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate", "Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate", "Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo", "Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate"]}, {"type": "DRUG", "name": "Placebo to indacaterol", "description": "Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.", "armGroupLabels": ["Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate", "Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate", "Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo", "Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Each Treatment Period (Day 7)", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at Baseline and at the end of each treatment period. The analysis included period baseline FEV1 as covariate.", "timeFrame": "Baseline to the end of each treatment period (Day 7)"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose on Day 1", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at Baseline and on Day 1. The analysis included period baseline FEV1 as covariate.", "timeFrame": "Baseline to Day 1"}, {"measure": "Time to Peak Forced Expiratory Volume in 1 Second (FEV1) on Day 1 and Day 7", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards at 5, 15, and 30 minutes; 1 hour, 1 hour 30 minutes; and 2, 4, and 12 hours post-dose on Day 1 and Day 7.", "timeFrame": "Day 1 and Day 7"}, {"measure": "Percentage of Patients Using Rescue Medication During Each 7 Day Treatment Period", "description": "Patients recorded use of rescue medication (salbutamol/albuterol multi-dose inhaler) as the number of puffs taken in respective preceding 12 hours morning and evening in a diary. Patient with any use of rescue medication (any number of puffs \\> 0) was included to calculate endpoint.", "timeFrame": "Baseline to the end of each treatment period (Day 7)"}, {"measure": "Indacaterol Exposure (AUC[0-24 Hours]) at the End of Each 7 Day Treatment Period", "description": "Venous blood samples for pharmacokinetic evaluation were collected at 15 and 30 minutes; and 1, 2, 4, 12, and 24 hours post-dose at the end of each 7 day treatment period and were analyzed using a LC-MS/MS assay. Area under the concentration-time curve up to 24 hours (AUC\\[0-24 hours\\]) was calculated from concentration-time data and recorded sampling times using non-compartmental methods.", "timeFrame": "End of each treatment period (Day 7)"}, {"measure": "Indacaterol Exposure (Cmax) at the End of Each 7 Day Treatment Period", "description": "Venous blood samples for pharmacokinetic evaluation were collected at 15 and 30 minutes; and 1, 2, 4, 12, and 24 hours post-dose at the end of each 7 day treatment period and were analyzed using a LC-MS/MS assay. Maximum (peak) plasma drug concentration after drug administration (Cmax) was calculated from concentration-time data and recorded sampling times using non-compartmental methods.", "timeFrame": "End of each treatment period (Day 7)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Non-smoker male and female adult patients aged 18-75 years inclusive, who have signed an informed consent form prior to initiation of any study-related procedure, including any adjustments to asthma medication prior to screening.\n* Patients with asthma, receiving daily treatment with inhaled corticosteroid.\n* Patients with a forced expiratory volume in 1 second (FEV1) during screening of \u2265 50% of the predicted normal value for the patient.\n* Body mass index (BMI) must be within the range 18-32 kg/m\\^2 (inclusive).\n* Able to communicate well with the investigator and comply with the requirements of the study.\n\nExclusion criteria:\n\n* A urine cotinine level greater than the local laboratory lowest level of quantification (LOQ of 500 ng/ml or lower).\n* Patients who have had a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to screening.\n* Patients who have had an emergency room visit for an asthma attack/exacerbation within 6 weeks prior to screening or any time between screening and pre-dose on day 1 of the study.\n* Patients who have had a respiratory tract infection within 4 weeks prior to screening or any time between screening and pre-dose on day 1 of the study.\n* Patients who require the use of \u2265 8 inhalations per day of the short-acting \u03b22-agonist salbutamol/albuterol (100 \u03bcg/90 \u03bcg salbutamol/albuterol metered dose inhaler \\[MDI\\] or equivalent dose of a dry-powder inhaler \\[DPI\\]) on any 2 consecutive days from screening to randomization.\n* Patients diagnosed with chronic obstructive pulmonary disease (COPD) as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (2008).\n* Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation. Previous participation in a study with either the investigational or comparator drugs does not exclude a patient from participation in this study.\n* Significant illness.\n* History of being immunocompromised, including a positive human immunodeficiency virus (HIV) test result (ELISA and Western blot).\n* A positive hepatitis B surface antigen (HBsAg) or hepatitis C test result.\n* Patients who are considered vulnerable as per ICH GCP guidelines.\n* Patients with a history of hypersensitivity to indacaterol or to similar drugs including untoward reactions to sympathomimetic amines or inhaled medication or any component thereof.\n* Treatments for asthma and allied conditions:\n* The following treatments should not be used unless they have been stabilized prior to screening: antihistamines, inhaled nasal cromolyn, inhaled nasal corticosteroids, and maintenance immunotherapy.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Poitiers", "country": "France", "geoPoint": {"lat": 46.58333, "lon": 0.33333}}, {"facility": "Novartis Investigative Site", "city": "Wiesbaden", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "Novartis Investigative Site", "city": "Verona", "country": "Italy", "geoPoint": {"lat": 45.4299, "lon": 10.98444}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Indacaterol (Ind) Maleate-placebo-ind Xinafoate-ind Acetate", "description": "In treatment period 1, patients received indacaterol maleate 400 \u03bcg; in treatment period 2, patients received placebo to indacaterol; in treatment period 3, patients received indacaterol xinafoate 400 \u03bcg; and in treatment period 4, patients received indacaterol acetate 400 \u03bcg. Patients received each treatment for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "FG001", "title": "Indacaterol (Ind) Xinafoate-ind Maleate-ind Acetate-placebo", "description": "In treatment period 1, patients received indacaterol xinafoate 400 \u03bcg; in treatment period 2, patients received indacaterol maleate 400 \u03bcg; in treatment period 3, patients received indacaterol acetate 400 \u03bcg; and in treatment period 4, patients received placebo to indacaterol 400 \u03bcg. Patients received each treatment for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "FG002", "title": "Indacaterol (Ind) Acetate-ind Xinafoate-placebo-ind Maleate", "description": "In treatment period 1, patients received indacaterol acetate 400 \u03bcg; in treatment period 2, patients received indacaterol xinafoate 400 \u03bcg; in treatment period 3, patients received placebo to indacaterol; and in treatment period 4, patients received indacaterol maleate 400 \u03bcg. Patients received each treatment for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "FG003", "title": "Placebo-indacaterol (Ind) Acetate-ind Maleate-ind Xinafoate", "description": "In treatment period 1, patients received placebo to indacaterol; in treatment period 2, patients received indacaterol acetate 400 \u03bcg; in treatment period 3, patients received indacaterol maleate 400 \u03bcg; and in treatment period 4, patients received indacaterol xinafoate 400 \u03bcg. Patients received each treatment for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "periods": [{"title": "Treatment Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Period 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Entire Study Population", "description": "The entire study population included all 4 treatment groups who received the 3 salt forms of indacaterol 400 \u00b5g (maleate, acetate, and xinafoate) and placebo to indacaterol in 4 different sequences. The dose refers to 400 \u03bcg of free base indacaterol. Patients received each treatment for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "30"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "50", "spread": "12.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Each Treatment Period (Day 7)", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at Baseline and at the end of each treatment period. The analysis included period baseline FEV1 as covariate.", "populationDescription": "Efficacy analysis set: All randomized subjects that received at least 1 dose of study drug and had a baseline and at least 1 post-baseline measurement of FEV1.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline to the end of each treatment period (Day 7)", "groups": [{"id": "OG000", "title": "Indacaterol Maleate 400 \u03bcg", "description": "Patients received indacaterol maleate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol Acetate 400 \u03bcg", "description": "Patients received indacaterol acetate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol Xinafoate 400 \u03bcg", "description": "Patients received indacaterol xinafoate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo to Indacaterol", "description": "Patients received placebo to indacaterol once daily for 7 days via the Concept1 single-dose dry-powder inhaler. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "28"}, {"groupId": "OG003", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.186", "lowerLimit": "0.1079", "upperLimit": "0.2649"}, {"groupId": "OG001", "value": "0.190", "lowerLimit": "0.1133", "upperLimit": "0.2673"}, {"groupId": "OG002", "value": "0.194", "lowerLimit": "0.1164", "upperLimit": "0.2728"}, {"groupId": "OG003", "value": "-0.021", "lowerLimit": "-0.0982", "upperLimit": "0.0558"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose on Day 1", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at Baseline and on Day 1. The analysis included period baseline FEV1 as covariate.", "populationDescription": "Efficacy analysis set: All randomized subjects that received at least 1 dose of study drug and had a baseline and at least 1 post-baseline measurement of FEV1.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline to Day 1", "groups": [{"id": "OG000", "title": "Indacaterol Maleate 400 \u03bcg", "description": "Patients received indacaterol maleate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol Acetate 400 \u03bcg", "description": "Patients received indacaterol acetate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol Xinafoate 400 \u03bcg", "description": "Patients received indacaterol xinafoate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo to Indacaterol", "description": "Patients received placebo to indacaterol once daily for 7 days via the Concept1 single-dose dry-powder inhaler. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "29"}, {"groupId": "OG003", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.161", "lowerLimit": "0.0877", "upperLimit": "0.2344"}, {"groupId": "OG001", "value": "0.185", "lowerLimit": "0.1129", "upperLimit": "0.2572"}, {"groupId": "OG002", "value": "0.205", "lowerLimit": "0.1325", "upperLimit": "0.2792"}, {"groupId": "OG003", "value": "0.008", "lowerLimit": "-0.0649", "upperLimit": "0.0819"}]}]}]}, {"type": "SECONDARY", "title": "Time to Peak Forced Expiratory Volume in 1 Second (FEV1) on Day 1 and Day 7", "description": "FEV1 was measured with spirometry conducted according to internationally accepted standards at 5, 15, and 30 minutes; 1 hour, 1 hour 30 minutes; and 2, 4, and 12 hours post-dose on Day 1 and Day 7.", "populationDescription": "Efficacy analysis set: All randomized subjects that received at least 1 dose of study drug and had a baseline and at least 1 post-baseline measurement of FEV1.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Hours", "timeFrame": "Day 1 and Day 7", "groups": [{"id": "OG000", "title": "Indacaterol Maleate 400 \u03bcg", "description": "Patients received indacaterol maleate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol Acetate 400 \u03bcg", "description": "Patients received indacaterol acetate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol Xinafoate 400 \u03bcg", "description": "Patients received indacaterol xinafoate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo to Indacaterol", "description": "Patients received placebo to indacaterol once daily for 7 days via the Concept1 single-dose dry-powder inhaler. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "29"}, {"groupId": "OG003", "value": "29"}]}], "classes": [{"title": "Day 1, N=29, 30, 29, 29", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.00", "lowerLimit": "3.000", "upperLimit": "6.125"}, {"groupId": "OG001", "value": "2.13", "lowerLimit": "1.500", "upperLimit": "3.000"}, {"groupId": "OG002", "value": "1.50", "lowerLimit": "1.040", "upperLimit": "2.500"}, {"groupId": "OG003", "value": "2.25", "lowerLimit": "1.500", "upperLimit": "12.085"}]}]}, {"title": "Day 7, N=28, 29, 28, 29", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.00", "lowerLimit": "2.000", "upperLimit": "4.000"}, {"groupId": "OG001", "value": "2.50", "lowerLimit": "1.500", "upperLimit": "4.000"}, {"groupId": "OG002", "value": "3.00", "lowerLimit": "1.250", "upperLimit": "12.000"}, {"groupId": "OG003", "value": "12.38", "lowerLimit": "11.710", "upperLimit": "13.875"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Using Rescue Medication During Each 7 Day Treatment Period", "description": "Patients recorded use of rescue medication (salbutamol/albuterol multi-dose inhaler) as the number of puffs taken in respective preceding 12 hours morning and evening in a diary. Patient with any use of rescue medication (any number of puffs \\> 0) was included to calculate endpoint.", "populationDescription": "Efficacy analysis set: All randomized subjects that received at least 1 dose of study drug and had a baseline and at least 1 post-baseline measurement of FEV1.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to the end of each treatment period (Day 7)", "groups": [{"id": "OG000", "title": "Indacaterol Maleate 400 \u03bcg", "description": "Patients received indacaterol maleate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol Acetate 400 \u03bcg", "description": "3Patients received indacaterol acetate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol Xinafoate 400 \u03bcg", "description": "Patients received indacaterol xinafoate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo to Indacaterol", "description": "Patients received placebo to indacaterol once daily for 7 days via the Concept1 single-dose dry-powder inhaler. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "29"}, {"groupId": "OG003", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "17"}, {"groupId": "OG003", "value": "21"}]}]}]}, {"type": "SECONDARY", "title": "Indacaterol Exposure (AUC[0-24 Hours]) at the End of Each 7 Day Treatment Period", "description": "Venous blood samples for pharmacokinetic evaluation were collected at 15 and 30 minutes; and 1, 2, 4, 12, and 24 hours post-dose at the end of each 7 day treatment period and were analyzed using a LC-MS/MS assay. Area under the concentration-time curve up to 24 hours (AUC\\[0-24 hours\\]) was calculated from concentration-time data and recorded sampling times using non-compartmental methods.", "populationDescription": "Pharmacokinetic analysis set: All subjects with evaluable pharmacokinetic parameter data. Number of subjects varied due to missing values.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg * hr/mL", "timeFrame": "End of each treatment period (Day 7)", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 400 \u03bcg", "description": "Patients received indacaterol acetate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol Maleate 400 \u03bcg", "description": "Patients received indacaterol maleate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol Xinafoate 400 \u03bcg", "description": "Patients received indacaterol xinafoate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "27"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5159", "spread": "27.9", "lowerLimit": "3003", "upperLimit": "10893"}, {"groupId": "OG001", "value": "5434", "spread": "30.7", "lowerLimit": "3581", "upperLimit": "13634"}, {"groupId": "OG002", "value": "5170", "spread": "24.2", "lowerLimit": "3312", "upperLimit": "8349"}]}]}]}, {"type": "SECONDARY", "title": "Indacaterol Exposure (Cmax) at the End of Each 7 Day Treatment Period", "description": "Venous blood samples for pharmacokinetic evaluation were collected at 15 and 30 minutes; and 1, 2, 4, 12, and 24 hours post-dose at the end of each 7 day treatment period and were analyzed using a LC-MS/MS assay. Maximum (peak) plasma drug concentration after drug administration (Cmax) was calculated from concentration-time data and recorded sampling times using non-compartmental methods.", "populationDescription": "Pharmacokinetic analysis set: All subjects with evaluable pharmacokinetic parameter data. Number of subjects varied due to missing values.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg/mL", "timeFrame": "End of each treatment period (Day 7)", "groups": [{"id": "OG000", "title": "Indacaterol Acetate 400 \u03bcg", "description": "Patients received indacaterol acetate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol Maleate 400 \u03bcg", "description": "Patients received indacaterol maleate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol Xinafoate 400 \u03bcg", "description": "Patients received indacaterol xinafoate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "720", "spread": "35.5", "lowerLimit": "338", "upperLimit": "1550"}, {"groupId": "OG001", "value": "753", "spread": "40.6", "lowerLimit": "322", "upperLimit": "1870"}, {"groupId": "OG002", "value": "664", "spread": "26.4", "lowerLimit": "397", "upperLimit": "1150"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Baseline to the end of the study (approximately 11 weeks)", "description": "Safety population: All subjects who received at least 1 dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Indacaterol Acetate 400 \u03bcg", "description": "Patients received indacaterol acetate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 5, "otherNumAtRisk": 30}, {"id": "EG001", "title": "Indacaterol Maleate 400 \u03bcg", "description": "Patients received indacaterol maleate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 29, "otherNumAffected": 4, "otherNumAtRisk": 29}, {"id": "EG002", "title": "Indacaterol Xinafoate 400 \u03bcg", "description": "Patients received indacaterol xinafoate 400 \u03bcg once daily for 7 days via the Concept1 single-dose dry-powder inhaler. The dose refers to 400 \u03bcg of free base indacaterol. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 29, "otherNumAffected": 7, "otherNumAtRisk": 29}, {"id": "EG003", "title": "Placebo to Indacaterol", "description": "Patients received placebo to indacaterol once daily for 7 days via the Concept1 single-dose dry-powder inhaler. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 29, "otherNumAffected": 5, "otherNumAtRisk": 29}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 29}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 29}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 29}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 29}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 30}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 29}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 29}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 29}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Romania"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000030272", "term": "Maleic acid"}], "ancestors": [{"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M13031", "name": "Oxymetazoline", "relevance": "LOW"}, {"id": "M13561", "name": "Phenylephrine", "relevance": "LOW"}, {"id": "M245808", "name": "Maleic acid", "asFound": "Fast", "relevance": "HIGH"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}